ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the captioned matter, please find enclosed herewith Revised Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2020, received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliance Certificate Pursuant To Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2020
With reference to the captioned subject, we hereby confirm that all activities in relation to both physical and electronic share transfer facility are maintained by the Company's Registrar and Share Transfer Agent viz. Link Intime India Private Limited, which is a SEBI approved Category-I Registrar & Transfer Agent, registered with the Securities and Exchange Board of India (SEBI Registration Number: INR000004058). We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board Meeting Intimation for Board Meeting To Consider Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2020
ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2020 ,inter alia, to consider and approve With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Friday, 22nd May, 2020, inter-alia to consider and approve Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2020. Pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company which was closed from 1st April, 2020, will re-open 48 hours after the declaration of the financial results. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Doxycycline Hyclate Tablets USP, 100 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. How R&D; spends make Alembic Pharmaceuticals a good buy
Aggressive capex, manufacturing capabilities for US and a change in domestic strategy make the stock attractive ALEMBIC PHARMACEUTICALS LTD. - 533573 - Alembic Pharmaceuticals Limited Announces Its Joint Venture, Aleor Dermaceuticals Ltd., Received Establishment Inspection Report (EIR) For Its Formulation Facility At Karkhadi
This is to inform the exchange that Aleor Dermaceuticals Ltd. (Aleor), a 60:40 Joint Venture between Alembic Pharmaceuticals Ltd. (Alembic) and Orbicular Pharmaceutical Technologies Pvt. Ltd. (Orbicular), has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection carried out by them at Aleor''s Formulation Facility at Karakhadi, Gujarat, India during the period from 6th January, 2020 to 8th January, 2020. We request you to kindly take the same on record ALEMBIC PHARMACEUTICALS LTD. - 533573 - Voluntary Action Indicated (VAI) By USFDA
We would like to inform that the US Food and Drug Administration (USFDA) has classified the Alembic Pharmaceuticals General Oral Solid Formulation Facility located at Panelav as Voluntary Action Indicated (VAI). Inspection at the said Facility was conducted by USFDA from 9th March, 2020 to 13th March, 2020. VAI means USFDA accepted the Company's response to its observations. We request you to kindly take the same on record.
After strong FY20, Alembic Pharma's FY21 outlook, too, remains firm
As traction in US business continues, the rebound in domestic growth to double digits will keep overall momentum steady
Alembic Pharma shares jump 5% after robust Q4 profit; volumes surge 250%
US generics business increased 84 percent to Rs 577 crore for the quarter and 53 percent to Rs 1,976 crore for FY20. Indian formulations business grew by 13 percent.